The CDKN2A (p16) gene and human cancer

Molecular Medicine

Volumn 3, Issue 1, 1997, Pages 5-20

  Foulkes, William D ^a   Flanders, Tamar Y ^a   Pollock, Pamela M ^b   Hayward, Nicholas K ^b  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR PROTEIN; PROTEIN P16;

BREAST CANCER; CANCER SUSCEPTIBILITY; CELL CYCLE; COLON CANCER; CONTROLLED STUDY; CYTOGENETICS; FAMILIAL CANCER; GENE MUTATION; GENETIC LINKAGE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MELANOMA; MULTIPLE CANCER; OVARY CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW; SOMATIC CELL GENETICS; TUMOR SUPPRESSOR GENE;

EID: 0030899774     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401664     Document Type: Review

References (93)

1. Cairns P, Mao L, Merlo A, et al. (1994) Rates of p 16 (MTS1) mutations in primary tumors with 9p loss. Science 265: 415-417.
2. Izumoto S, Arita N, Ohnishi T, Hiraga S, Taki T, Hayakawa T. (1995) Homozygous deletions of P16(INK4A)/MTS1 and P15 (INK4B)/MTS2 genes in glioma cells and primary glioma tissues. Cancer Lett. 97: 241-247.
3. Bergman W, Watson P, de Jong J, Lynch HT, Fusaro RM. (1990) Systemic cancer and the FAMMM syndrome. Br. J. Cancer 61: 932-936.
4. Hollstein M, Rice K, Greenblatt MS, et al. (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucl. Acids Res. 22: 3551-3555.
5. Li FP, Fraumeni JF, Jr, Mulvihill JJ, et al. (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res. 48: 5358-5362.
6. Fountain JW, Karayiorgou M, Ernstoff MS, et al. (1992) Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. Natl. Acad. Sci. U.S.A. 89: 10557-10561.
7. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440.
8. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. (1992) Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258: 1148-1152.
9. Goldstein AM, Dracopoli NC, Engelstein M, Fraser MC, Clark WH, Jr, Tucker MA. (1994) Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am. J. Hum. Genet. 54: 489-496.
10. Nancarrow DJ, Mann GJ, Holland EA, et al. (1993) Confirmation of chromosome 9p linkage in familial melanoma. Am. J. Hum. Genet. 53: 936-942.
11. Gruis NA, Sandkuijl LA, Weber JL, et al. (1993) Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect of naevus count. Melanoma Res. 3: 271-277.
12. MacGeoch C, Bishop JA, Bataille V, et al. (1994) Genetic heterogeneity in familial malignant melanoma. Hum. Mol. Genet. 3: 2195-2200.
13. Okamoto A, Demetrick DJ, Spillare EA, et al. (1994) Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. U.S.A. 91: 11045-11049.
14. Ohta M, Nagai H, Shimizu M, et al. (1994) Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res. 54: 5269-5272.
15. Spruck CH, 3rd, Gonzalez-Zulueta M, Shibata A, et al. (1994) p16 gene in uncultured tumours. Nature 370: 183-184.
16. Cairns P, Polascik TJ, Eby Y, et al. (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet. 11: 210-212.
17. Merlo A, Herman JG, Mao L, et al. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1: 686-692.
18. Herman JG, Merlo A, Mao L, et al. (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55: 4525-4530.
19. Gonzalez-Zulueta M, Bender CM, Yang AS, et al. (1995) Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55: 4531-4535.
20. Reed AL, Califano J, Cairus P, Wesira WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroe H, Bartek J, Sidransky D. (1996) High frequency of p16 (CDKN2/MTS1/1NK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56:3630-3633.
21. Hussussian CJ, Struewing JP, Goldstein AM, et al. (1994) Germline p16 mutations in familial melanoma. Nature Genet. 8: 15-21.
22. Gruis NA, van der Velden PA, Sandkuijl LA, et al. (1995) Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet. 10: 351-353.
23. Walker GJ, Hussussian CJ, Flore JF, et al. (1995) Mutations of the CDKN2/p16(INK4) gene in Australian melanoma kindreds. Hum Mol. Genet. 4: 1845-1852.
24. Sun S, Narod SA, Foulkes WD. (1996) A p16 mutation in a family with multiple cancers [abstract]. Eur J Hum Genet. 4: 13.
25. Goldstein AM, Fraser MC, Struewing JP, et al. (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N. Engl. J. Med. 333: 970-974.
26. Ciotti P, Strigini P, Bianchiscarra G. (1996) Familial melanoma and pancreatic cancer. N. Engl. J. Med. 334: 469-470.
27. Ranade K, Hussussian CJ, Sikorski RS, et al. (1995) Mutations associated with familial melanoma impair p16INK4 function. Nature Genet. 10: 114-116.
28. Lynch HT, Fusaro RM, Pester J, et al. (1981) Tumour spectrum in the FAMMM syndrome. Br. J. Cancer 44: 553-560.
29. Greene MH, Tucker MA, Clark WH, Jr, Kraemer KH, Elder DE, Fraser MC. (1987) Hereditary melanoma and the dysplastic nevus syndrome: The risk of cancers other than melanoma. J. Am. Acad. Dermatol. 16: 792-797.
30. Gutman M, Cnaan A, Inbar M, et al. (1991) Are malignant melanoma patients at higher risk for a second cancer? Cancer 68: 660-665.
31. Linehan WM, Lerman MI, Zbar B. (1995) Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 273: 564-570.
32. Gayther SA, Warren W, Mazoyer S, et al. (1995) Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genet. 11: 428-433.
33. Whelan AJ, Bartsch D, Goodfellow PJ. (1995) Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N. Engl. J. Med. 333: 975-977.
34. Yarbrough WG, Aprelikova O, Pei H, Olshan AF, Liu ET. (1996) Familial tumor syndrome associated with a germline non-functional p16(INK4a) allele. J. Natl. Cancer Inst. 88: 1489-1491.
35. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756.
36. Pollock PM, Pearson JV, Hayward NK. (1996) Compilation of somatic mutations of the CDKN2 gene in human cancers - non-random distribution of base substitutions. Genes Chromosome Cancer 15: 77-88.
37. Smith-Sorensen B, Hovig E. (1996) CDKN2A (P16(INK4A)) somatic and germline mutations. Hum. Mutat. 7: 294-303.
38. Jen J, Harper JW, Bigner SH, et al. (1994) Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54: 6353-6358.
39. Yoshida S, Todoroki T, Ichikawa Y, et al. (1995) Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res. 55: 2756-2760.
40. Luca M, Xie SH, Gutman M, Huang SY, Bareli M. (1995) Abnormalities in the CDKN2 (P16(INK4)/MTS-1) gene in human melanoma cells - relevance to tumor growth and metastasis. Oncogene 11: 1399-1402.
41. Nakagawa K, Conrad NK, Williams JP, Johnson BE, Kelley MJ. (1995) Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene 11: 1843-1851.
42. Huang LY, Goodrow TL, Zhang SY, Kleinszanto AJP, Chang H, Ruggeri BA. (1996) Deletion and mutation analyses of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res. 56: 1137-1141.
43. Zariwala M, Liu E, Xiong Y. (1996) Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15(INK4B) and p18(INK4C) in tumor-derived cell lines and primary tumors. Oncogene 12: 451-455.
44. Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W. (1996) Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 110: 1215-1224.
45. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP. (1996) Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet. Cytogenet. 86: 136-142.
46. Wiest J, Frankin W, Otstot J, Anderson M. (1996) Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung [abstract]. Proc. Am. Assoc. Cancer Res. 37: 593.
47. Brenner AJ, Aldaz CM. (1995) Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res. 55: 2892-2895.
48. Xu L, Sgroi D, Sterner CJ, et al. (1994) Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res. 54: 5262-5264.
49. Campbell IG, Foulkes WD, Beynon G, Davis M, Englefield P. (1995) LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int. J. Cancer 63: 222-225.
50. Hatta Y, Hirama T, Takeuchi S, et al. (1995) Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J Urol. 154: 1954-1957.
51. Fearon ER, Cho KR, Nigro JM, et al. (1990) Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247: 49-56.
52. Thiagalingam S, Lengauer C, Leach FS, et al. (1996) Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nature Genet. 13: 343-346.
53. Riggins GJ, Thiagalingam S, Rozenblum E, et al. (1996) Mad-related genes in the human. Nature Genet. 13: 347-349.
54. Reed JA, Loganzo F, Jr, Shea CR, et al. (1995) Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 55: 2713-2718.
55. Caldas C, Hahn SA, da Costa LT, et al. (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet. 8: 27-32.
56. Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA, Goodfellow PJ. (1995) Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosome Cancer 14: 189-195.
57. Bartsch D, Shevlin DW, Callery MP, Norton JA, Wells SA, Goodfellow PJ. (1996) Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. J. Natl. Cancer Inst. 88: 680-682.
58. Eiriksdottir G, Sigurdsson A, Jonasson JG, et al. (1995) Loss of heterozygosity on chromosome 9 in human breast cancer - association with clinical variables and genetic changes at other chromosome regions. Int. J. Cancer 64: 378-382.
59. Holland EA, Beaton SC, Becker TM, et al. (1995) Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11: 2289-2294.
60. Hansson J, Platz A, Linder S, Mansson BE, Lundqvist E, Inganas P, et al. (1996) Germine p16 mutations are rare in Swedish melanoma families [abstract]. Proc. Am. Assoc. Cancer Res. 37: 186.
61. Kamb A, Shattuck-Eidens D, Eeles R, et al. (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8: 23-26.
62. Liu L, Lassam NJ, Slingerland JM, et al. (1995) Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 11: 405-412.
63. Borg A, Johansson U, Johannsson O, et al. (1996) Novel germline p16 mutation in familial malignant melanoma in Southern Sweden. Cancer Res. 56: 2497-2500.
64. Ueki K, Rubio MP, Ramesh V, et al. (1994) MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum. Mol. Genet. 3: 1841-1845.
65. Musgrove EA, Lilischkis R, Cornish AL, et al. (1995) Expression of the cyclin-dependent kinase inhibitors p16(INK4), p15(INK4B) and p21 (WAF1/CIP1) in human breast cancer. Int. J. Cancer 63: 584-591.
66. Ohnishi H, Kawamura M, Ida K, et al. (1995) Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 86: 1269-1275.
67. Uzawa K, Suzuki H, Yokoe H, Tanzawa H, Sato K. (1995) Mutational state of p16/CDKN2 and VHL genes in squamous-cell carcinoma of the oral cavity. Int. J. Oncol. 7: 895-899.
68. Calabro V, Strazzullo M, LaMantia G, Fedele M, Paulin C, Fusco A. (1996) Status and expression of the p16(INK4) gene in human thyroid-tumour cell lines. Int. J. Cancer 67: 29-34.
69. Nakamaki T, Kawamata N, Schwaller J, et al. (1995) Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. Br. J. Haematol. 91: 139-149.
70. De Vos S, Miller CW, Takeuchi S, Gombart AF, Cho SK, Koeffler HP. (1995) Alterations of CDKN2 (p16) in non-smal cell lung cancer. Genes Chromosome Cancer 14: 164-170.
71. Yang CH, Perentesis JP. (1996) Novel mutations of the CDKN2A gene in leukemia: Potential insight into the structural basis of CDKN2A action [abstract]. Proc Am Assoc Cancer Res 37: 590.
72. Okajima E, Fukuda T, Okita S, Tsutsumi M, Hirao Y, Konishi Y. (1996) Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers. Cancer Lett. 103: 227-231.
73. Platz A, Ringborg U, Lagerlof B, Lundqvist E, Sevigny P, Inganas M. (1996) Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Br. J. Cancer 73: 344-348.
74. Rasool O, Heyman M, Brandter LB, et al. (1995) p15ink4B and p16ink4 gene inactivation in acute lymphocytic leukemia. Blood 85: 3431-3436.
75. Uchida T, Watanabe T, Kinoshita T, Murate T, Saito H, Hotta T. (1995) Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas. Blood 86: 2724-2731.
76. Esteve A, Martelplanche G, Sylla BS, Hollstein M, Hainaut P, Montesano R. (1996) Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas. Int. J. Cancer 66: 301-304.
77. Ueki K, Ono Y, Hensen JW, Efird JT, von Deimling A, Louis DN. (1996) CDKN2/p16 or Rb alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56: 150-153.
78. Shimizu T, Sekiya T. (1995) Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancer. Int. J. Cancer 63: 616-620.
79. Konishi N, Hiasa Y, Tsuzuki T, et al. (1996) Detection of Rb, p16/CDKN2 and P15 (INK4B) gene alterations with immunohistochemical studies in human prostate carcinomas. Int. J. Oncol. 8: 107-112.
80. Maelandsmo GM, Florenes VA, Hovig E, et al. (1996) Involvement of the pRb/p16/CDK4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br. J. Cancer 73: 909-916.
81. Ohta M, Berd D, Shimizu M, et al. (1996) Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int. J. Cancer 65: 762-767.
82. Rusin MR, Okamoto A, Chorazy M, et al. (1996) Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. Int. J. Cancer 65: 734-739.
83. Haider MA, Cao XB, Manshouri T, Chan LL, Glassman A, Kantarjian HM. (1995) p16(INK4A) and p15(INK4B) gene deletions in primary leukemias. Blood 86: 311-315.
84. Kyritsis AP, Zhang BH, Zhang W, et al. (1996) Mutations of the p16 gene in gliomas. Oncogene 12: 63-67.
85. Berns EMJJ, Klijn JGM, Smid M, Vanstaveren IL, Gruis NA, Foekens JA. (1995) Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br. J. Cancer 72: 964-967.
86. Nakao M, Yokota S, Kaneko H, et al. (1996) Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia - mutations of CDKN2 are observed preferentially in T lineage. Leukemia 10: 249-254.
87. Tung WS, Shevlin DW, Bartsch D, Norton JA, Wells SA, Goodfellow PJ. (1996) Infrequent CDKN2 mutation in human differentiated thyroid cancers. Mol. Carcinog. 15: 5-10.
88. Qin LX, Tang ZY, Liu KD, et al. (1996) Alterations of CDKN2(p16/MTS1) exon 2 in human hepatocellular carcinoma. Oncol. Rep. 3: 405-408.
89. Miyamoto H, Kubota Y, Fujinami K, et al. (1995) Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer - p16 mutations occur only in low-grade and superficial bladder cancers. Oncol. Res. 7: 327-330.
90. Cayuela JM, Madani A, Sanhes L, Stern MH, Sigaux F. (1996) Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 87: 2180-2186.
91. Gonzalez-Zulueta M, Shibata A, Ohneseit PF, et al. (1995) High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. J. Natl. Cancer. Inst. 87: 1383-1393.
92. Sonoda Y, Yoshimoto T, Sekiya T. (1995) Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene 11: 2145-2149.
93. Igaki H, Sasaki H, Tachimori Y, et al. (1995) Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res. 55: 3421-3423.